| Project/Area Number |
16390439
|
|---|
| Research Category |
Grant-in-Aid for Scientific Research (B)
|
| Allocation Type | Single-year Grants |
|---|
| Section | 一般 |
|---|
| Research Field |
Orthopaedic surgery
|
|---|
| Research Institution | 独立行政法人国立病院機構(大阪医療センター臨床研究部) (2006-2007)
Osaka University (2004-2005) |
|---|
Principal Investigator |
UEDA Takafumi 独立行政法人国立病院機構(大阪医療センター臨床研究部), Institute for Clinical Research, Osaka National Hospita, M.D. (00324773)
|
|---|
| Co-Investigator(Kenkyū-buntansha) |
MYOUI Akira Osaka University Hospital, Medical Center for Translational Research, Associate Professor (10263261)
YOSHIKAWA Hideki Osaka University Graduate School of Medicine, Department of Orthopaedics, Professor/Chairman (60191558)
|
|---|
| Project Period (FY) |
2004 – 2007
|
| Project Status |
Completed (Fiscal Year 2007)
|
| Budget Amount *help |
¥10,630,000 (Direct Cost: ¥10,000,000、Indirect Cost: ¥630,000)
Fiscal Year 2007: ¥2,730,000 (Direct Cost: ¥2,100,000、Indirect Cost: ¥630,000)
Fiscal Year 2006: ¥2,100,000 (Direct Cost: ¥2,100,000)
Fiscal Year 2005: ¥2,100,000 (Direct Cost: ¥2,100,000)
Fiscal Year 2004: ¥3,700,000 (Direct Cost: ¥3,700,000)
|
|---|
| Keywords | malignant bone & soft-tissue tumor / sarcomas / tumor-specific immnotherapy / WT1 gene / SSX gene / DC vaccine therapy |
|---|
| Research Abstract |
To develop tumor-specific immunotherapy for bone and soft-tissue sarcomas, we have planned and conducted translational and clinical researches as follows ; 1) We analyzed the overexpression of WT1 gene and its correlation with prognosis in 52 patients with soft-tissue sarcoma, elucidating WT1 overexpression being as a prognostic factor for patiets with soft-tissue sarcoma and WT1 peptide to be a candidate of molecular targets for tumor-specific immunotherapy for sarcomas(Cancer 106(10) : 2233-2240, 2006) . 2) We have started a phase I/II clinical trial of tumor-specific immunotherapy using WT1 peptide for a variety of solid cansers including bone and soft-tissue sarcomas(30 cases) from April 2004, to evaluate the efficacy and toxicity of WT1 peptide. Twenty cases of locally advanced and/or metastatic bone and soft-tissue sarcomas were enrolled to the trial until March 2008. There are 8 SD(stable disease) , 11PD(progressive disease) , and one suspended case by patient's decision, without PR(partial response) /or CR(complete response) cases. We have not yet experienced severe toxicity in WT1 vaccinations except for local redness/swelling of intracutaneous injection sites. 3) We have performed an experimental DC(denritic cell) immunotherapy using C3H murine model of lung metastases from osteosarcoma(LM8) , which was originally established in our laboratory, and demonstrated the anti-tumor activity of DC vaccine immunotherapy for primary tumors and lung metastases of LM8 osteosarcoma cells(Clin Orthop 453 : 318-327, 2006).
For further projects, we will progress the phase I/II clinical trial of tumor-specific immunotherapy using WT1 peptide for bone and soft-tissue sarcomas(30 cases) , and also develop a new molecular targeting therapy for bone and soft-tissue sarcomas focusing SSX gene products as a cancer-testis antigen frequently expressed not only in sarcomas but also in a variety of solid cancers.
|
